- Chandigarh, seventeenth June: In a historic breakthrough for the Pharmaceutical trade within the nation, Venus Cures Restricted received a 10-year lengthy authorized battle that challenged patent claimed by French pharmaceutical agency SCR Pharmatop for producing the intravenous paracetamol answer in India.
In a call dated 4th June, 2021, the Indian Patent Workplace determined in favour of Venus Cures and upheld its resolution for revocation of the Indian patent on the grounds that the method lacked any ingenious step that made it superior to different present options.
Venus’s opposition was meant to take away any Indian Patent hurdle in manufacturing of Intravenous Paracetamol answer in India. As intravenous paracetamol performs a vital function in managing irritation and fever, therefore the revocation of this patent is an encouraging growth for the healthcare sector within the nation reeling below the present pandemic.
Sharing the event with the important thing stakeholders of the corporate,